505052-64-2 Usage
Uses
Used in Pharmaceutical Industry:
4-(5-BROMO-3-NITRO-PYRIDIN-2-YL)-MORPHOLINE is used as a building block for the synthesis of pharmaceuticals due to its potential biological activity and the versatility of the morpholine ring, which can be further modified to create new drug candidates.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(5-BROMO-3-NITRO-PYRIDIN-2-YL)-MORPHOLINE is utilized as a precursor in the development of agrochemicals, leveraging its chemical properties to enhance crop protection and management products.
Used in Materials Science Research:
4-(5-BROMO-3-NITRO-PYRIDIN-2-YL)-MORPHOLINE is employed as a component in materials science research to explore its potential in creating new materials with specific properties, such as improved stability or reactivity, for various applications.
Overall, 4-(5-BROMO-3-NITRO-PYRIDIN-2-YL)-MORPHOLINE's role in chemical synthesis and drug discovery highlights its importance across different scientific and industrial fields.
Check Digit Verification of cas no
The CAS Registry Mumber 505052-64-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,5,0,5 and 2 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 505052-64:
(8*5)+(7*0)+(6*5)+(5*0)+(4*5)+(3*2)+(2*6)+(1*4)=112
112 % 10 = 2
So 505052-64-2 is a valid CAS Registry Number.
505052-64-2Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AND THEIR USES
-
Page/Page column 68, (2011/01/05)
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
